milrinone has been researched along with Acute Disease in 33 studies
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To prospectively test whether a strategy that includes short-term use of milrinone in addition to standard therapy can improve clinical outcomes of patients hospitalized with an exacerbation of chronic heart failure." | 9.10 | Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. ( Adams, KF; Benza, R; Bourge, R; Califf, RM; Colucci, WS; Cuffe, MS; Gheorghiade, M; Massie, BM; O'Connor, CM; Pina, I; Quigg, R; Silver, MA, 2002) |
| "To assess the hemodynamic effects of milrinone in a 48h intravenous infusion in patients with severe congestive heart failure (CHF) (NYHA class III or IV)." | 9.08 | [Value of the use of milrinone in the treatment of acute crisis in patients with congestive heart failure]. ( Bianco, AC; Freire, RB; Gun, C; Piegas, LS; Ramos, RF; Timerman, A, 1995) |
| "5, 5, or 10 mg) of milrinone in 31 patients with acute or decompensated heart failure." | 9.08 | Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure. ( Hayakawa, H; Kamishima, G; Kanmatsuse, K; Motomiya, T; Murata, M; Saitoh, S; Saitoh, T; Seino, Y; Takano, T; Watanabe, K, 1995) |
| "The purpose of this study was to compare the hemodynamic and clinical effects of milrinone, a vasodilating and positive inotropic agent, with those of dobutamine in patients with congestive heart failure (CHF) following acute myocardial infarction (AMI)." | 9.08 | Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. ( Berk, MR; DeMaria, AN; DeWood, MA; Karlsberg, RP; Lasher, KP, 1996) |
| "The hemodynamic effects and safety of milrinone, a phosphodiesterase inhibitor, were studied in 57 patients in the acute phase of cardiac failure." | 9.07 | [Efficacy of intravenous milrinone in the treatment of acute congestive cardiac failure. Results of a French multicenter study]. ( Bory, M; Brochier, M; Dubois-Randé, JL; Guérot, C; Jan, F; Lambert, H; Le Bloc'h, Y; Pony, JC; Sacrez, A; Vacheron, A, 1993) |
| "To determine the effect of dobutamine versus milrinone on out-of-hospital mortality in the treatment of patients with acute decompensated heart failure (ADHF)." | 7.85 | Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure. ( Biskupiak, J; Bress, AP; King, JB; Munger, MA; Sainski-Nguyen, A; Shah, RU, 2017) |
| "The purpose of this study was to determine whether a low-dose β-blocker, in combination with milrinone, improves cardiac function in acute decompensated heart failure (ADHF) with tachycardia." | 7.78 | Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. ( Doi, M; Fukuta, S; Kobayashi, S; Matsuzaki, M; Murakami, W; Nao, T; Okamura, T; Okuda, S; Susa, T; Tanaka, T; Wada, Y; Yamada, J; Yano, M, 2012) |
| "Our initial experience demonstrates that administration of levosimendan in patients with severe chronic heart failure not responsive to standard intravenous inotropic treatment might result in a significant clinical and hemodynamic improvement and that, in selected patients, it might be life saving." | 7.77 | [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children]. ( Jovicić, B; Kosutić, J; Nikolić, L; Prijić, S; Rakić, S; Stajević, M; Vukomanović, V, 2011) |
| "Both milrinone and UK 343-664 partially reversed thromboxane-induced pulmonary hypertension, with a notable decrease in mean pulmonary artery pressure and pulmonary vascular resistance and a concomitant increase in cardiac output." | 7.72 | Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension. ( Beaver, T; Kirby, DS; Lobato, EB; Naik, B; Urdaneta, F; Willert, JL, 2004) |
| "To evaluate the effects of milrinone (MIL) on hemodynamics and lung water content, we used 10 mongrel dogs with pulmonary hypertension (PH)." | 7.68 | Effects of milrinone on lung water content in dogs with acute pulmonary hypertension. ( Kobayashi, K; Matsumoto, A; Tajimi, K; Tanaka, H, 1992) |
| " For these purposes, we reviewed data available from randomized controlled trials on short-term, intermittent, and long-term use of intravenous inodilator agents (dobutamine, dopamine, and milrinone) in AHFS." | 6.43 | Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. ( Bayram, M; De Luca, L; Gheorghiade, M; Massie, MB, 2005) |
| "Pulmonary hypertension was present in all groups following CPB." | 5.35 | Treating pulmonary hypertension post cardiopulmonary bypass in pigs: milrinone vs. sildenafil analog. ( Beaver, T; Kirby, DS; Klodell, C; Lobato, EB; Muehlschlegel, JD; Sidi, A; Urdaneta, F, 2008) |
| "Pulmonary hypertension was induced with a continuous infusion of the thromboxane analogue, U46619." | 5.33 | Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. ( Beaver, T; Kirby, DS; Klodell, C; Lobato, EB; Muehlschlegel, J; Sidi, A, 2006) |
| "We analyzed data from the OPTIME-CHF (Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure) study, a randomized trial of intravenous milrinone versus placebo in 949 patients hospitalized with ADHF." | 5.12 | Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. ( Califf, RM; Cuffe, MS; Echols, MR; Felker, GM; Garg, J; Gheorghiade, M; O'Connor, CM; Pieper, KS; Thomas, KL, 2006) |
| "To prospectively test whether a strategy that includes short-term use of milrinone in addition to standard therapy can improve clinical outcomes of patients hospitalized with an exacerbation of chronic heart failure." | 5.10 | Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. ( Adams, KF; Benza, R; Bourge, R; Califf, RM; Colucci, WS; Cuffe, MS; Gheorghiade, M; Massie, BM; O'Connor, CM; Pina, I; Quigg, R; Silver, MA, 2002) |
| "5, 5, or 10 mg) of milrinone in 31 patients with acute or decompensated heart failure." | 5.08 | Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure. ( Hayakawa, H; Kamishima, G; Kanmatsuse, K; Motomiya, T; Murata, M; Saitoh, S; Saitoh, T; Seino, Y; Takano, T; Watanabe, K, 1995) |
| "To assess the hemodynamic effects of milrinone in a 48h intravenous infusion in patients with severe congestive heart failure (CHF) (NYHA class III or IV)." | 5.08 | [Value of the use of milrinone in the treatment of acute crisis in patients with congestive heart failure]. ( Bianco, AC; Freire, RB; Gun, C; Piegas, LS; Ramos, RF; Timerman, A, 1995) |
| "The purpose of this study was to compare the hemodynamic and clinical effects of milrinone, a vasodilating and positive inotropic agent, with those of dobutamine in patients with congestive heart failure (CHF) following acute myocardial infarction (AMI)." | 5.08 | Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. ( Berk, MR; DeMaria, AN; DeWood, MA; Karlsberg, RP; Lasher, KP, 1996) |
| "The hemodynamic effects and safety of milrinone, a phosphodiesterase inhibitor, were studied in 57 patients in the acute phase of cardiac failure." | 5.07 | [Efficacy of intravenous milrinone in the treatment of acute congestive cardiac failure. Results of a French multicenter study]. ( Bory, M; Brochier, M; Dubois-Randé, JL; Guérot, C; Jan, F; Lambert, H; Le Bloc'h, Y; Pony, JC; Sacrez, A; Vacheron, A, 1993) |
| "Recent data have confirmed the heterogeneous nature of patients admitted with acute decompensated heart failure, and the limitations of the current therapeutic regimens with diuretics, intravenous vasodilators (ie, nitroglycerin, nitroprusside), and intravenous inotropes (ie, dobutamine, milrinone)." | 4.82 | A rational approach for the treatment of acute heart failure: current strategies and future options. ( Sharma, M; Teerlink, JR, 2004) |
| "Milrinone (Inocor-Sanofi-Winthrop) represents a second generation phosphodiesterase inhibitor currently approved for intravenous administration in the treatment of decompensated congestive heart failure." | 4.79 | Milrinone: basic and clinical pharmacology and acute and chronic management. ( Hastillo, A; Hess, ML; Shipley, JB; Tolman, D, 1996) |
| "To determine the effect of dobutamine versus milrinone on out-of-hospital mortality in the treatment of patients with acute decompensated heart failure (ADHF)." | 3.85 | Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure. ( Biskupiak, J; Bress, AP; King, JB; Munger, MA; Sainski-Nguyen, A; Shah, RU, 2017) |
| "The purpose of this study was to determine whether a low-dose β-blocker, in combination with milrinone, improves cardiac function in acute decompensated heart failure (ADHF) with tachycardia." | 3.78 | Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. ( Doi, M; Fukuta, S; Kobayashi, S; Matsuzaki, M; Murakami, W; Nao, T; Okamura, T; Okuda, S; Susa, T; Tanaka, T; Wada, Y; Yamada, J; Yano, M, 2012) |
| "Our initial experience demonstrates that administration of levosimendan in patients with severe chronic heart failure not responsive to standard intravenous inotropic treatment might result in a significant clinical and hemodynamic improvement and that, in selected patients, it might be life saving." | 3.77 | [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children]. ( Jovicić, B; Kosutić, J; Nikolić, L; Prijić, S; Rakić, S; Stajević, M; Vukomanović, V, 2011) |
| "To describe the clinical management of acute decompensated heart failure (ADHF) in patients receiving intravenous treatment with dobutamine, milrinone, or nesiritide, and to evaluate differences, based on treatment received, in the in-hospital mortality rate, length of stay (LOS), total health care costs, and 30-day hospital readmission rate." | 3.73 | Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. ( Arnold, LM; Carroll, NV; Crouch, MA; Oinonen, MJ, 2006) |
| "Both milrinone and UK 343-664 partially reversed thromboxane-induced pulmonary hypertension, with a notable decrease in mean pulmonary artery pressure and pulmonary vascular resistance and a concomitant increase in cardiac output." | 3.72 | Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension. ( Beaver, T; Kirby, DS; Lobato, EB; Naik, B; Urdaneta, F; Willert, JL, 2004) |
| "To evaluate the effects of milrinone (MIL) on hemodynamics and lung water content, we used 10 mongrel dogs with pulmonary hypertension (PH)." | 3.68 | Effects of milrinone on lung water content in dogs with acute pulmonary hypertension. ( Kobayashi, K; Matsumoto, A; Tajimi, K; Tanaka, H, 1992) |
| "Milrinone is a phosphodiesterase F-III inhibitor with positive inotropic and vasodilating activities." | 2.68 | Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators. ( Hayakawa, H; Katoh, K; Momomura, S; Seino, Y; Takano, T, 1996) |
| " For these purposes, we reviewed data available from randomized controlled trials on short-term, intermittent, and long-term use of intravenous inodilator agents (dobutamine, dopamine, and milrinone) in AHFS." | 2.43 | Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. ( Bayram, M; De Luca, L; Gheorghiade, M; Massie, MB, 2005) |
| "Patients with acute congestive heart failure generally present with profound fluid retention states and dyspnea due to pulmonary edema." | 2.41 | New therapeutic choices in the management of acute congestive heart failure. ( Young, JB, 2001) |
| "Myocarditis is a common cause for acute heart failure in the pediatric population." | 1.51 | Does myocardial strain remain abnormal long after normalization of ejection fraction in patients with acute myocarditis? ( Bourget, L; Garg, A; Manalo, R; Swaminathan, S, 2019) |
| "The echocardiographic presence of mild aortic regurgitation combined with left ventricular hypocontractility in a structurally normal heart should alert the physician to the presence of underlying hypertension." | 1.39 | Neonatal circulatory failure due to acute hypertensive crisis: clinical and echocardiographic clues. ( Allegaert, K; Brown, S; Cools, B; Eyskens, B; Gewillig, M; Heying, R; Levtchenko, E; Louw, J; Smits, A; Thewissen, L, 2013) |
| "Pulmonary hypertension was present in all groups following CPB." | 1.35 | Treating pulmonary hypertension post cardiopulmonary bypass in pigs: milrinone vs. sildenafil analog. ( Beaver, T; Kirby, DS; Klodell, C; Lobato, EB; Muehlschlegel, JD; Sidi, A; Urdaneta, F, 2008) |
| "Pulmonary hypertension was induced with a continuous infusion of the thromboxane analogue, U46619." | 1.33 | Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. ( Beaver, T; Kirby, DS; Klodell, C; Lobato, EB; Muehlschlegel, J; Sidi, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (21.21) | 18.2507 |
| 2000's | 19 (57.58) | 29.6817 |
| 2010's | 7 (21.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| King, JB | 1 |
| Shah, RU | 1 |
| Sainski-Nguyen, A | 1 |
| Biskupiak, J | 1 |
| Munger, MA | 1 |
| Bress, AP | 1 |
| Manalo, R | 1 |
| Bourget, L | 1 |
| Garg, A | 1 |
| Swaminathan, S | 1 |
| Gebhard, CE | 1 |
| Rochon, A | 1 |
| Cogan, J | 1 |
| Ased, H | 1 |
| Desjardins, G | 1 |
| Deschamps, A | 1 |
| Gavra, P | 1 |
| Lebon, JS | 1 |
| Couture, P | 1 |
| Ayoub, C | 1 |
| Levesque, S | 1 |
| Elmi-Sarabi, M | 1 |
| Couture, EJ | 1 |
| Denault, AY | 1 |
| Louw, J | 1 |
| Brown, S | 1 |
| Thewissen, L | 1 |
| Smits, A | 1 |
| Eyskens, B | 1 |
| Heying, R | 1 |
| Cools, B | 1 |
| Levtchenko, E | 1 |
| Allegaert, K | 1 |
| Gewillig, M | 1 |
| Perez, M | 1 |
| Kumar, TK | 1 |
| Figueroa, M | 1 |
| Johnson, J | 1 |
| Absi, MA | 1 |
| Urdaneta, F | 2 |
| Lobato, EB | 3 |
| Beaver, T | 3 |
| Muehlschlegel, JD | 1 |
| Kirby, DS | 3 |
| Klodell, C | 2 |
| Sidi, A | 2 |
| Donlan, SM | 1 |
| Quattromani, E | 1 |
| Pang, PS | 1 |
| Gheorghiade, M | 4 |
| Prijić, S | 1 |
| Rakić, S | 1 |
| Nikolić, L | 1 |
| Jovicić, B | 1 |
| Stajević, M | 1 |
| Vukomanović, V | 1 |
| Kosutić, J | 1 |
| Kobayashi, S | 1 |
| Susa, T | 1 |
| Tanaka, T | 1 |
| Murakami, W | 1 |
| Fukuta, S | 1 |
| Okuda, S | 1 |
| Doi, M | 1 |
| Wada, Y | 1 |
| Nao, T | 1 |
| Yamada, J | 1 |
| Okamura, T | 1 |
| Yano, M | 1 |
| Matsuzaki, M | 1 |
| Young, JB | 1 |
| Lewis, DA | 1 |
| Gurram, NR | 1 |
| Abraham, WT | 2 |
| Akers, WS | 1 |
| Sharma, M | 1 |
| Teerlink, JR | 1 |
| Willert, JL | 1 |
| Naik, B | 1 |
| Adams, KF | 2 |
| Fonarow, GC | 1 |
| Costanzo, MR | 1 |
| Berkowitz, RL | 1 |
| LeJemtel, TH | 1 |
| Cheng, ML | 1 |
| Wynne, J | 1 |
| Dec, GW | 1 |
| Bayram, M | 1 |
| De Luca, L | 1 |
| Massie, MB | 1 |
| Muehlschlegel, J | 1 |
| Arnold, LM | 1 |
| Crouch, MA | 1 |
| Carroll, NV | 1 |
| Oinonen, MJ | 1 |
| Echols, MR | 1 |
| Felker, GM | 1 |
| Thomas, KL | 1 |
| Pieper, KS | 1 |
| Garg, J | 1 |
| Cuffe, MS | 2 |
| Califf, RM | 2 |
| O'Connor, CM | 2 |
| Saltzman, HE | 1 |
| Sharma, K | 1 |
| Mather, PJ | 1 |
| Rubin, S | 1 |
| Adams, S | 1 |
| Whellan, DJ | 1 |
| Goto, Y | 1 |
| Buckley, MS | 1 |
| Feldman, JP | 1 |
| Heywood, JT | 1 |
| Khan, TA | 1 |
| Seino, Y | 2 |
| Takano, T | 2 |
| Hayakawa, H | 2 |
| Kanmatsuse, K | 1 |
| Saitoh, S | 1 |
| Saitoh, T | 1 |
| Kamishima, G | 1 |
| Watanabe, K | 1 |
| Motomiya, T | 1 |
| Murata, M | 1 |
| Dubois-Randé, JL | 1 |
| Guérot, C | 1 |
| Jan, F | 1 |
| Brochier, M | 1 |
| Sacrez, A | 1 |
| Vacheron, A | 1 |
| Bory, M | 1 |
| Lambert, H | 1 |
| Pony, JC | 1 |
| Le Bloc'h, Y | 1 |
| Gun, C | 1 |
| Piegas, LS | 1 |
| Bianco, AC | 1 |
| Freire, RB | 1 |
| Ramos, RF | 1 |
| Timerman, A | 1 |
| Shipley, JB | 1 |
| Tolman, D | 1 |
| Hastillo, A | 1 |
| Hess, ML | 1 |
| Momomura, S | 1 |
| Katoh, K | 1 |
| Karlsberg, RP | 1 |
| DeWood, MA | 1 |
| DeMaria, AN | 1 |
| Berk, MR | 1 |
| Lasher, KP | 1 |
| Ricksten, S | 1 |
| Benza, R | 1 |
| Bourge, R | 1 |
| Colucci, WS | 1 |
| Massie, BM | 1 |
| Pina, I | 1 |
| Quigg, R | 1 |
| Silver, MA | 1 |
| Poole-Wilson, PA | 1 |
| Tanaka, H | 1 |
| Tajimi, K | 1 |
| Matsumoto, A | 1 |
| Kobayashi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Milrinone Versus Dobutamine in a Heterogeneous Population of Critically Ill Patients[NCT03207165] | Phase 4 | 192 participants (Actual) | Interventional | 2017-08-30 | Completed | ||
| The Effects of Intra Aortic Balloon Pump Prior to Revascularization on Mortality of Patients With Acute Coronary Syndrome Complicated With Cardiogenic Shock[NCT03635840] | 92 participants (Anticipated) | Interventional | 2018-01-04 | Recruiting | |||
| Comparison of Dobutamine Versus Milrinone for Renal Recovery in Patients With Cardiorenal Syndrome-A Prospective Cohort Study in Patients With Acute Decompensated Heart Failure[NCT02644057] | Phase 2 | 0 participants (Actual) | Interventional | 2016-03-31 | Withdrawn (stopped due to Could not enroll patients) | ||
| Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output: A Single Center, Randomized, Non-Blinded, and Parallel Study (PRIORITY-ADHF Study)[NCT02767024] | Phase 4 | 0 participants (Actual) | Interventional | 2018-05-01 | Withdrawn (stopped due to No patients enrolled) | ||
| Perioperative Use of Levosimendan in Patients With Impaired Right Ventricular Function Undergoing Cardiac Surgery With Cardiopulmonary Bypass[NCT05063370] | Phase 2 | 40 participants (Actual) | Interventional | 2021-08-18 | Active, not recruiting | ||
| Innovative Strategies for Implementing New CHF Guideline Recommendations[NCT00012974] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2005-11-30 | Completed | ||
| 2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB[NCT00819377] | Phase 2 | 124 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for milrinone and Acute Disease
| Article | Year |
|---|---|
Therapy for acute heart failure syndromes.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiotonic Agents; Digoxin; Diuretics; Dobutamine; Drug The | 2009 |
New therapeutic choices in the management of acute congestive heart failure.
Topics: Acute Disease; Heart Failure; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide | 2001 |
A rational approach for the treatment of acute heart failure: current strategies and future options.
Topics: Acute Disease; Adenosine; Cardiotonic Agents; Catheterization, Swan-Ganz; Dobutamine; Drug Therapy; | 2004 |
Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.
Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Dopamine; Heart Failure; Humans; Milrinone; Syndrome | 2005 |
Renal dysfunction in heart failure patients: what is the evidence?
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2007 |
[How to use PDE III inhibitors].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acute Disease; Blood Pressure; Cyclic Nucleotide Phosphodiester | 2007 |
The use of vasoactive therapy for acute decompensated heart failure: hemodynamic and renal considerations.
Topics: Acute Disease; Cardiac Output; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Kidney; Milr | 2007 |
Milrinone: basic and clinical pharmacology and acute and chronic management.
Topics: Acute Disease; Administration, Oral; Calcium Channels; Cardiac Output; Cardiotonic Agents; Clinical | 1996 |
[The pulmonary vasodilatory effect of inhaled prostacyclin and milrinone in heart].
Topics: Acute Disease; Administration, Inhalation; Cardiac Surgical Procedures; Cyclic AMP; Drug Synergism; | 2001 |
7 trials available for milrinone and Acute Disease
| Article | Year |
|---|---|
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial.
Topics: Acute Disease; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Black or African American; Car | 2006 |
Hemodynamic effects and pharmacokinetics of oral milrinone for short-term support in acute heart failure.
Topics: Acute Disease; Administration, Oral; Aged; Female; Heart Failure; Hemodynamics; Humans; Male; Milrin | 1995 |
[Efficacy of intravenous milrinone in the treatment of acute congestive cardiac failure. Results of a French multicenter study].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Female; Heart Failure | 1993 |
[Value of the use of milrinone in the treatment of acute crisis in patients with congestive heart failure].
Topics: Acute Disease; Adult; Aged; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Infusio | 1995 |
Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators.
Topics: Acute Disease; Aged; Cardiac Output, Low; Double-Blind Method; Drug Administration Schedule; Female; | 1996 |
Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group.
Topics: Acute Disease; Aged; Cardiotonic Agents; Dobutamine; Echocardiography; Electrocardiography, Ambulato | 1996 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hea | 2002 |
17 other studies available for milrinone and Acute Disease
| Article | Year |
|---|---|
Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure.
Topics: Acute Disease; Aged; Cardiotonic Agents; Cohort Studies; Dobutamine; Female; Heart Failure; Hospital | 2017 |
Does myocardial strain remain abnormal long after normalization of ejection fraction in patients with acute myocarditis?
Topics: Acute Disease; Adolescent; Atrioventricular Block; Cardiotonic Agents; Disease Progression; Echocard | 2019 |
Acute Right Ventricular Failure in Cardiac Surgery During Cardiopulmonary Bypass Separation: A Retrospective Case Series of 12 Years' Experience With Intratracheal Milrinone Administration.
Topics: Acute Disease; Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Echocardiography, Transesophageal; | 2019 |
Neonatal circulatory failure due to acute hypertensive crisis: clinical and echocardiographic clues.
Topics: Acute Disease; Antihypertensive Agents; Aortic Valve Insufficiency; Arterial Pressure; Body Weight; | 2013 |
Case 2: Acute-onset tachypnea, tachycardia, and reduced activity in a 16-month-old girl.
Topics: Acute Disease; Antibodies, Viral; Cardiotonic Agents; Coxsackievirus Infections; Diagnosis, Differen | 2015 |
Treating pulmonary hypertension post cardiopulmonary bypass in pigs: milrinone vs. sildenafil analog.
Topics: Acute Disease; Animals; Blood Pressure; Cardiopulmonary Bypass; Hypertension, Pulmonary; Milrinone; | 2008 |
[Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
Topics: Acute Disease; Adolescent; Cardiotonic Agents; Child, Preschool; Dobutamine; Heart Failure; Humans; | 2011 |
Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Cardiotonic Agents; C | 2012 |
Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure.
Topics: Acute Disease; Aged; Endpoint Determination; Heart Failure; Hemodynamics; Humans; Length of Stay; Mi | 2003 |
Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-GMP Phosphodiestera | 2004 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Agents; Dobutamine; Female; Heart Failure; Ho | 2005 |
Acute decompensated heart failure: the shrinking role of inotropic therapy.
Topics: Acute Disease; Cardiovascular Agents; Dobutamine; Heart Failure; Humans; Milrinone; Natriuretic Pept | 2005 |
Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-AMP Phosphodiestera | 2006 |
Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Topics: Acute Disease; Aged; Cardiotonic Agents; Cohort Studies; Dobutamine; Female; Health Care Costs; Hear | 2006 |
Nebulized milrinone use in a pulmonary hypertensive crisis.
Topics: Acute Disease; Administration, Inhalation; Adult; Antihypertensive Agents; Blood Pressure; Bronchodi | 2007 |
Treatment of acute heart failure: out with the old, in with the new.
Topics: Acute Disease; Atrial Natriuretic Factor; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Natr | 2002 |
Effects of milrinone on lung water content in dogs with acute pulmonary hypertension.
Topics: Acute Disease; Animals; Body Water; Catheterization; Disease Models, Animal; Dogs; Hemodynamics; Hyp | 1992 |